Anna Sandberg

Anna Sandberg

Auto-generated profile, based on publicly available information

Anna Sandberg

Sweden)

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
EJEsteban Jodar
Esteban Jodar
MMMarie Michelsen
Marie Michelsen
WPWilliam Polonsky
William Polonsky
RRRosangela Réa
Rosangela Réa
ASAnna Sandberg
Anna Sandberg
SBStephen Bain
Stephen Bain
Aim: To assess what drives change in health‐related quality of life (HRQoL) in type 2 diabetes in the SUSTAIN 6 trial and identify potential mediators of the treatment effect of semaglutide on HRQoL scores. Materials and Methods: The Short Form (SF)‐36v2® questionnaire [comprising physical component summary (PCS) and mental component summary (MCS)] was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis. This post‐hoc analysis assessed change in PCS and MCS using the following factors as parameter/covariate, using descriptive statistics and linear regressions: major adverse cardiac events, hypoglycaemia, gastrointestinal adverse events, at least one episode of nausea, vomiting or diarrhoea, and change in glycated haemoglobin (HbA1c), body weight, blood pressure, heart rate and estimated glomerular filtration rate. Results: Mean change in overall PCS score was +1.0 with semaglutide versus +0.4 with placebo, and +0.5 versus −0.2 for MCS. The treatment effect of semaglutide versus placebo (unadjusted estimate) was 0.7 [(95% confidence interval 0.1, 1.2); P = 0.018] on PCS and this was reduced when adjusted for change in HbA1c [0.4 (−0.2, 1.0), P = .167] and body weight [0.3 (−0.3, 0.9), P = .314]. The unadjusted treatment effect on MCS [0.7 (−0.0, 1.5), P = .054] was only reduced when adjusted for change in HbA1c [0.3 (−0.4, 1.1), P = .397]. When adjusting for all other parameters separately, the estimated effect of semaglutide on PCS and MCS qualitatively did not change. Conclusions: Semaglutide improved HRQoL versus placebo; greater improvements with semaglutide versus placebo were possibly mediated, in part, by change in HbA1c and body weight. Clinicaltrials.gov : NCT01720446 (SUSTAIN 6).

28 August 2026 in European Heart Journal
Verified
Journal Article
Closed access
Maria BäckMaria Bäck
Maria Bäck
MWMatthias Wilhelm
Matthias Wilhelm
TMThimo Marcin
Thimo Marcin
FMFelipe Machado
Felipe Machado
ASAnna Sandberg
Anna Sandberg
GMGuzal Mullabayeva
Guzal Mullabayeva

1 January 2020 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
ASAnna Sandberg
Anna Sandberg
ÅCÅsa Cider
Åsa Cider
LJLennart Jivegård
Lennart Jivegård
JNJoakim Nordanstig
Joakim Nordanstig
SWSusanna Wittboldt
Susanna Wittboldt
Maria BäckMaria Bäck
Maria Bäck

2 August 2022 in European Journal of Cardiovascular Nursing
Verified
Journal Article
Closed access
PDF file
ASAnna Sandberg
Anna Sandberg
Maria BäckMaria Bäck
Maria Bäck
ÅCÅsa Cider
Åsa Cider
LJLennart Jivegård
Lennart Jivegård
BSBirgitta Sigvant
Birgitta Sigvant
JNJoakim Nordanstig
Joakim Nordanstig
Aims: Supervised exercise is a guideline-recommended treatment in intermittent claudication (IC). Hospital-based supervised exercise programmes (SEPs) are underutilized, while home-based structured exercise programmes (HSEPs) have attracted interest. The results from HSEP in IC are inconsistent and may confer no benefit over walk advice (WA) and be less effective than SEP. The aim of the study was to compare the effectiveness of best medical treatment, including Nordic pole WA alone, or WA + SEP or WA + HSEP for patients with IC. Methods and results: This three-armed, multicentre randomized clinical trial enrolled patients with IC; all patients received best medical treatment including walking poles and the advice of regular Nordic pole walking (WA). For HSEP and SEP, additional exercise programmes were provided. The primarily investigated hypothesis was a non-inferiority analysis of SEP vs. HSEP regarding the 6-min walk test (6MWT) maximum distance, with a pre-defined non-inferiority margin of 50 m. Supporting outcomes included muscle endurance tests and the walking impairment questionnaire. Outcomes were assessed at baseline, 3, 6, and 12 months by a blinded evaluator. Altogether 166 patients (mean age 72 years; 59% males) were randomized. In HSEP and SEP, 24 and 26% patients, respectively, were fully exercise adherent. All three groups improved pain-free walking distance over time, but there were no significant intergroup differences. The intergroup 6MWT difference between SEP and HSEP from 0 to 12 months was –11.6 m, 95% confidence interval: –36.4 to 13.0 m (i.e. within the pre-specified non-inferiority margin). Conclusion: The HSEP was non-inferior to SEP in patients with IC. There were no significant differences observed between the three groups at 1 year. Registration: ClinicialTrials.gov: NCT02341716.

14 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HUHildigunnur Ulfsdottir
Hildigunnur Ulfsdottir
Maria BäckMaria Bäck
Maria Bäck
ÅCÅsa Cider
Åsa Cider
LJLennart Jivegård
Lennart Jivegård
ASAnna Sandberg
Anna Sandberg
MSMikael Svensson
Mikael Svensson
Hospital-based supervised exercise (SEP) is a guideline-recommended intervention for patients with intermittent claudication (IC). However, due to the limited availability of SEP, home-based structured exercise programs (HSEP) have become increasingly popular alongside the “go home and walk” advice. We evaluated the cost-effectiveness of walk advice (WA) with Nordic pole walking vs. SEP combined with WA or HSEP combined with WA. We used data from the SUNFIT RCT (NCT02341716) to measure quality-adjusted life-years (QALYs) over a 12-month follow-up, and economic costs were obtained from a hospital cost-per-patient accounting system. Incremental cost-effectiveness ratios (ICERs) were calculated, and uncertainty was assessed using nonparametric bootstrapping. The average health-care-cost per patient was similar in the WA (EUR 1781, n = 51) and HSEP (EUR 1820, n = 48) groups but higher in the SEP group (EUR 4619, n = 50, p-value < 0.01). Mean QALYs per patient during the follow-up were similar with no statistically significant differences. The findings do not support SEP as a cost-effective treatment for IC, as it incurred significantly higher costs without providing additional health improvements over WA with or without HSEP during the one-year observation period. The analysis also suggested that HSEP may be cost-effective compared to WA, but only with a 64% probability.

11 November 2008 in IEEE Software
Verified
Journal Article
Closed access
ASAnna Börjesson Sandberg
Anna Börjesson Sandberg
LMLars Mathiassen
Lars Mathiassen
Process improvement projects depend on the active participation of managers and senior engineers. At the telecom company Ericsson, change agents were frustrated that requests to participate in improvement projects often precipitated behavior from colleagues that hampered progress. However, rather than accepting slowdowns, the change agents started to ask why managers and senior engineers reacted this way even though Ericsson is highly committed to process improvement. In this article, we show how to analyze slowdown behavior, increase commitment and reinforce progress.